Ireland - English - HPRA (Health Products Regulatory Authority)

essential pharma (m) limited - lithium carbonate - film-coated tablet - 250 mg milligram(s) - lithium; lithium

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - gefitinib, quantity: 250 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; povidone; sodium lauryl sulfate; magnesium stearate; hypromellose; macrogol 300; iron oxide red; iron oxide yellow; titanium dioxide - iressa is indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer (nsclc), whose tumours express activating mutations of the egfr tyrosine kinase.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ciprofloxacin hydrochloride, quantity: 291 mg (equivalent: ciprofloxacin, qty 250 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate type a; microcrystalline cellulose; stearic acid; purified talc; colloidal anhydrous silica; croscarmellose sodium; povidone; hypromellose; magnesium stearate; titanium dioxide; macrogol 6000 - ciprofloxacin sandoz is indicated for the treatment of infections caused by susceptible organisms in the following conditions: urinary tract infections, gonorrhoeal urethritis and cervicitis, gastroenteritis, bronchial infections, skin and skin structure infections, bone and joint infections, chronic bacterial prostatitis of mild to moderate severity. typhoid and paratyphoid infections and infections due to multiresistant staph. aureus are excluded from the above due to insufficient data. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the medicine of choice in cases with gram-positive infections, such as pneumonia due to strep. pneumoniae. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of n. gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin sandoz may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin sandoz is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - clarithromycin, quantity: 250 mg - tablet, film coated - excipient ingredients: sorbitan mono-oleate; pregelatinised maize starch; titanium dioxide; povidone; propylene glycol; hypromellose; silicon dioxide; sorbic acid; stearic acid; purified talc; hyprolose; quinoline yellow; vanillin; magnesium stearate; croscarmellose sodium; microcrystalline cellulose - klacid (clarithromycin) is indicated for use in adults and children older than 12 years for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro-organisms in the conditions listed below: 1. acute streptococcal pharyngitis; 2. community acquired pneumonia due to chlamydia pneumoniae, mycoplasma pneumoniae, legionella pneumophila and streptococcus pneumoniae; 3. uncomplicated skin and skin structure infections due to staphylococcus aureus or streptococcus pyogenes; 4. disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare and skin and skin structure infections due to mycobacterium chelonae. clarithromycin should be used in combination with other antimycobacterial agents. 5. prevention of disseminated mycobacterium avium complex infection in hiv-infected adults with cd4 lymphocyte counts of < 75 cells/cubic mm. (see precautions) disseminated infection due to mycobacterium avium complex should be excluded by a negative blood culture prior to commencement of prophylaxis. 6. acute bacterial exacerbation of chronic bronchitis due to haemophilus influenzae, moraxella catarrhalis or streptococcus pneumoniae; 7. combination therapy for the treatment of peptic ulcer disease associated with helicobacter pylori infection. klacid (clarithromycin) is indicated for use in children for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro-organisms in the conditions listed below: 1. acute streptococcal pharyngitis and tonsillitis caused by streptococcus pyogenes; 2. community acquired pneumonia including infections due to chlamydia pneumoniae, mycoplasma pneumoniae and legionella pneumophila; 3. skin and skin structure infections (eg impetigo); 4. disseminated or localised infections due to mycobacterium avium or mycobacterium intracellulare in immunocompromised children, including those with hiv infection or aids. 5. acute otitis media. note: 1. penicillins are the drug of first choice in the treatment of acute otitis media. 2. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections including prophylaxis of rheumatic fever. clarithromycin appears to be as effective as phenoxymethylpenicillin in the eradication of streptococci from the nasopharynx, however substantial data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present. 3. there is insufficient evidence of efficacy to support the use of klacid in acute bronchitis in young children. 4. the data presented on infections of skin and skin structure were confined largely to mild to moderate infections such as impetigo.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefuroxime axetil, quantity: 300.72 mg (equivalent: cefuroxime, qty 250 mg) - tablet, film coated - excipient ingredients: propylene glycol; microcrystalline cellulose; croscarmellose sodium; hydrogenated vegetable oil; hypromellose; methyl hydroxybenzoate; colloidal anhydrous silica; propyl hydroxybenzoate; sodium lauryl sulfate; titanium dioxide; purified water; sodium benzoate; industrial methylated spirit - cefuroxime is indicated for the treatment of the following mild to moderately severe infections in adults caused by sensitive bacteria. . acute upper respiratory infections: otitis media, sinusitis, tonsillitis and pharyngitis. . acute exacerbations of chronic bronchitis, or acute bronchitis. . skin and skin structure infections, for example, furunculosis, pyoderma and impetigo. . acute uncomplicated gonococcal urethritis, and cervicitis due to non-penicillinase producing gonococci.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - gefitinib, quantity: 250 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; povidone; sodium lauryl sulfate; magnesium stearate; lactose monohydrate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - treatment of patients with locally advanced or metastatic non small cell lung cancer (nsclc) whose tumours express activating mutations of the egfr tyrosine kinase.

Australia - English - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - calcium carbonate,risedronate sodium -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

essential pharma ltd - lithium carbonate - oral tablet - 250mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - lithium carbonate - oral tablet - 250mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - lithium carbonate - oral tablet - 250mg